Blog

How can EHR linkage and federated learning verify oncology endpoints?

How EHR linkage and federated learning together can verify oncology endpoints: pragmatic linkage, federated survival models, and operational checklists for sites, with survey insights and patient-centered encouragement.

How to Join Trials: Fertility 35+, Hormone-Positive BC, Pregnancy Flu

Practical Q&A on joining trials for fertility after 35, hormone-positive breast cancer, and flu vaccination in pregnancy — with prep steps, global regulatory notes, stats, and advocacy resources.

Explainable AI & Federated Arms: Digital Twin Trials Roadmap

A practical Q&A on Explainable AI, federated synthetic control arms, digital twin planning and edge teleophthalmology — what patients and clinicians should ask before joining modern trials.

Future Trials: Spironolactone Repurposing & Glaucoma Device Surge

Repurposed spironolactone trials and a surge in glaucoma device research are reshaping recruitment, funding signals, and caregiver needs. Practical tips, survey data, and parent perspectives explain what matters now.

Caregiver Guide: Manage Meds, Telehealth & Senior Hormone Trials

A practical caregiver guide to enrolling seniors in hormone-positive breast cancer trials: manage multiple meds, leverage telehealth and mobility-friendly options, and use a simple checklist to streamline enrollment and communication with trial teams.

Predicting Trial Care: Home Derm Side-Effect Tactics & HNSCC Alerts

{ "content": "Clinical trial participants and study teams need practical, site-proof tactics when side effects and seasonal risks intersect with care delivered at home. This guide breaks down what to do for atopic dermatitis managed at home and how to spot and report immune-related changes in h...

Clinical trial Q&A: Patient questions for head and neck SCC trials

Top patient questions for head and neck SCC trials—eligibility, side effects, infection precautions, spironolactone safety, and trials for older adults with hormone-positive breast cancer, with real case insights and data-manager roles.

What will HNSCC investments and HR+ shifts mean for NYC trials in flu?

How do HNSCC investments and HR+ shifts affect NYC flu-season trials? Expect resource reallocation, enrollment seasonality, and special considerations for elderly and treatment-resistant patients—plus practical steps to improve participation.

Cross‑Modality Biomarker Trends: Federated, Compliant Oncology Trials

Analytical look at how federated architectures and cross‑modality biomarker workflows enable GDPR/HIPAA-compliant, adaptive oncology trials — and why patients can feel hopeful about more precise, accessible studies.